Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
2.84 HKD +1.43% Intraday chart for Sino Biopharmaceutical Limited -1.05% -18.16%
May. 24 Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials MT
May. 23 Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 122,159 118,610 83,443 74,593 58,030 48,228 - -
Enterprise Value (EV) 1 122,159 117,344 80,336 72,678 58,030 43,863 40,815 38,892
P/E ratio 45.1 x 42.8 x 6.07 x 33.2 x 25.1 x 17.8 x 15.6 x 14.6 x
Yield 0.75% 1.06% 1.46% 2.6% - 2.06% 2.4% 2.44%
Capitalization / Revenue 5.04 x 5.02 x 3.11 x 2.59 x 2.21 x 1.66 x 1.49 x 1.4 x
EV / Revenue 5.04 x 4.96 x 2.99 x 2.53 x 2.21 x 1.51 x 1.26 x 1.13 x
EV / EBITDA 19.1 x 20.4 x 15.5 x 10.5 x 8.96 x 5.95 x 5 x 4.47 x
EV / FCF 38.4 x 31.3 x 21.1 x 16.1 x - 8.55 x 8.54 x 6.56 x
FCF Yield 2.61% 3.19% 4.74% 6.2% - 11.7% 11.7% 15.2%
Price to Book 3.94 x 7.09 x 2.76 x 2.51 x 1.95 x 1.44 x 1.32 x 1.23 x
Nbr of stocks (in thousands) 18,810,956 18,789,999 18,756,114 18,481,249 18,399,239 18,337,124 - -
Reference price 2 6.494 6.312 4.449 4.036 3.154 2.630 2.630 2.630
Announcement Date 3/30/20 3/23/21 3/31/22 3/31/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,234 23,647 26,861 28,780 26,199 29,095 32,304 34,538
EBITDA 1 6,399 5,753 5,174 6,908 6,476 7,375 8,170 8,706
EBIT 1 4,840 4,098 4,182 5,861 5,439 6,149 6,823 7,349
Operating Margin 19.97% 17.33% 15.57% 20.37% 20.76% 21.13% 21.12% 21.28%
Earnings before Tax (EBT) 1 5,584 5,013 18,573 5,779 5,215 6,343 7,022 7,665
Net income 1 2,707 2,771 14,608 2,544 2,332 2,727 3,109 3,322
Net margin 11.17% 11.72% 54.38% 8.84% 8.9% 9.37% 9.62% 9.62%
EPS 2 0.1439 0.1474 0.7326 0.1215 0.1259 0.1475 0.1686 0.1804
Free Cash Flow 1 3,184 3,743 3,805 4,505 - 5,129 4,780 5,928
FCF margin 13.14% 15.83% 14.17% 15.65% - 17.63% 14.8% 17.16%
FCF Conversion (EBITDA) 49.76% 65.06% 73.54% 65.21% - 69.55% 58.51% 68.09%
FCF Conversion (Net income) 117.63% 135.08% 26.05% 177.12% - 188.06% 153.78% 178.45%
Dividend per Share 2 0.0488 0.0671 0.0648 0.1050 - 0.0543 0.0632 0.0641
Announcement Date 3/30/20 3/23/21 3/31/22 3/31/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 12,648 6,254 6,254 - - 15,194 13,587 15,277 10,922 15,317 13,484 15,910 15,635
EBITDA - - - - - - - - - - - - -
EBIT 2,417 525.1 525.1 - - 3,252 2,700 3,219 2,220 3,369 2,791 3,721 3,070
Operating Margin 19.11% 8.4% 8.4% - - 21.4% 19.87% 21.07% 20.33% 22% 20.7% 23.39% 19.63%
Earnings before Tax (EBT) - - - - - - - 3,224 1,991 - - - -
Net income - - - - - - - 1,259 1,073 - - - -
Net margin - - - - - - - 8.24% 9.83% - - - -
EPS 1 - 0.1500 0.1500 0.0500 0.0500 0.0920 0.0295 0.0678 0.0581 0.0800 0.0600 0.0900 0.0900
Dividend per Share - - - - - - - - - - - - -
Announcement Date 8/28/20 9/26/22 3/31/22 9/26/22 8/23/22 8/23/22 3/31/23 8/25/23 3/28/24 - - - -
1CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 1,266 3,107 1,915 - 4,364 7,412 9,336
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 3,184 3,743 3,805 4,505 - 5,129 4,780 5,928
ROE (net income / shareholders' equity) 8.97% 17.5% 62.1% 8.47% 7.75% 8.05% 8.73% 8.6%
ROA (Net income/ Total Assets) 5.01% 6.54% 27.1% 4.08% 3.65% 5.08% 5.2% 5.35%
Assets 1 54,040 42,371 53,877 62,304 63,836 53,705 59,819 62,067
Book Value Per Share 2 1.650 0.8900 1.610 1.610 1.620 1.830 1.990 2.140
Cash Flow per Share 2 0.2800 0.2800 0.2900 0.3300 - 0.3500 0.3900 0.4100
Capex 1 2,141 1,582 1,561 1,760 - 1,311 1,347 1,270
Capex / Sales 8.83% 6.69% 5.81% 6.12% - 4.51% 4.17% 3.68%
Announcement Date 3/30/20 3/23/21 3/31/22 3/31/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sino Biopharmaceutical Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
2.63 CNY
Average target price
4.256 CNY
Spread / Average Target
+61.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SINO BIOPHARMACEUTICAL LIMITED Stock Sino Biopharmaceutical Limited
-18.16% 6.66B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. Financials Sino Biopharmaceutical Limited